1. Home
  2. EHTH vs SPRO Comparison

EHTH vs SPRO Comparison

Compare EHTH & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo eHealth Inc.

EHTH

eHealth Inc.

HOLD

Current Price

$3.48

Market Cap

123.1M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.45

Market Cap

135.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHTH
SPRO
Founded
1997
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
123.1M
135.8M
IPO Year
2006
2017

Fundamental Metrics

Financial Performance
Metric
EHTH
SPRO
Price
$3.48
$2.45
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
$7.00
$5.00
AVG Volume (30 Days)
296.6K
227.1K
Earning Date
02-25-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$542,951,000.00
$40,549,000.00
Revenue This Year
$4.61
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$78.88
N/A
Revenue Growth
16.79
N/A
52 Week Low
$3.18
$0.51
52 Week High
$11.36
$3.22

Technical Indicators

Market Signals
Indicator
EHTH
SPRO
Relative Strength Index (RSI) 36.39 52.00
Support Level $3.43 $2.31
Resistance Level $3.67 $2.66
Average True Range (ATR) 0.20 0.09
MACD -0.07 -0.01
Stochastic Oscillator 4.35 34.78

Price Performance

Historical Comparison
EHTH
SPRO

About EHTH eHealth Inc.

eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: